Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

ABSTRACT:

Objective

Recommendations for the diagnosis of preclinical Alzheimer disease (AD) have been formulated by a workgroup of the National Institute on Aging and Alzheimer's Association. Three stages of preclinical AD were described. Stage 1 is characterized by abnormal levels of β-amyloid. Stage 2 represents abnormal levels of β-amyloid and evidence of brain neurodegeneration. Stage 3 includes the features of stage 2 plus subtle cognitive changes. Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their validity.

Methods

Using previously developed operational definitions of the 3 stages of preclinical AD, we examined

SUBMITTER: Knopman DS 

PROVIDER: S-EPMC3348848 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature